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Abstract
Hookworm infection is one of the most important parasitic infections of humans, possibly outranked only by malaria as a cause of
misery and suffering. An estimated 1.2 billion people are infected with hookworm in areas of rural poverty in the tropics and subtropics. Epidemiological data collected in China, Southeast Asia, and Brazil indicate that, unlike other soil-transmitted helminth
infections, the highest hookworm burdens typically occur in adult populations, including the elderly. Emerging data on the host
cellular immune responses of chronically infected populations suggest that hookworms induce a state of host anergy and immune
hyporesponsiveness. These features account for the high rates of hookworm reinfection following treatment with anthelminthic
drugs and therefore, the failure of anthelminthics to control hookworm. Despite the inability of the human host to develop naturally acquired immune responses to hookworm, there is evidence for the feasibility of developing a vaccine based on the successes
of immunizing laboratory animals with either attenuated larval vaccines or antigens extracted from the alimentary canal of adult
blood-feeding stages. The major antigens associated with each of these larval and adult hookworm vaccines have been cloned and
expressed in prokaryotic and eukaryotic systems. However, only eukaryotic expression systems (e.g., yeast, baculovirus, and insect cells) produce recombinant proteins that immunologically resemble the corresponding native antigens. A challenge for vaccinologists is to formulate selected eukaryotic antigens with appropriate adjuvants in order to elicit high antibody titers. In some
cases, antigen-specific IgE responses are required to mediate protection. Another challenge will be to produce anti-hookworm
vaccine antigens at high yield low cost suitable for immunizing large impoverished populations living in the developing nations
of the tropics.
Keywords: Hookworm; Necator, Ancylostoma, vaccines, recombinant proteins, expression systems

400 million of these infected individuals are children of
school age and 300 million suffer from heavy worm burdens sufficient to result in severe disease. Overall, it is believed that, together with schistosomiasis, the soil-transmitted helminth infections account for 40% of the global
morbidity caused by all infectious diseases, exclusive of
malaria (WHO, 2000).

1. “The Great Infection of Mankind”
The World Health Organization (WHO) estimates that
approximately two billion people worldwide are infected
with the soil-transmitted nematode helminths Ascaris
lumbricoides, Trichuris trichirua, and the hookworms Necator americanus and Ancylostoma duodenale. Approximately
1245
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Because they injure their human hosts directly by causing intestinal blood loss leading to iron deficiency and
protein malnutrition, some investigators implicate hookworms as the most important helminthic cause of global
disease burden. Professor Norman Stoll of the Rockefeller Institute and Foundation considered hookworms
“The Great Infection of Mankind” (Stoll, 1962), second
only to malaria as the major cause of human misery in the
tropics.
Despite its global importance hookworm has, until recently, been overlooked as a public health problem. There
are several reasons for this situation. Among them, hookworm disease and anemia, which result from parasiteinduced blood loss are frequently insidious and seldom
dramatic in their clinical presentation; they are not usually associated directly with high mortality. Therefore,
clinical experts often fail to link human hookworm infection to a significant cause of morbidity worldwide. Moreover, because of the misconception that hookworm could
be prevented by increased use of shoes in tropical countries, hookworm was often not deemed worthy of scientific study. Possibly for these reasons, hookworm was
not listed as one of the six major tropical infections of the
Tropical Disease Research (TDR) program established by
the WHO during the 1980s (Hotez et al., in press).
Our ignorance regarding the public health importance
of hookworm began to change during the early 1990s
when new quantitative estimates of disease burden based
on the concept of disability adjusted life years (DALYs)
revealed hookworm’s global impact (Murray and Lopez, 1996). DALY estimates determined that the disease
burden from hookworms exceeds three tropical infectious diseases under investigation in the WHO-TDR program: African trypanosomiasis, Chagas disease, and leprosy. Hookworm was also found to outrank dengue fever
(Murray and Lopez, 1996).
More recent DALY estimates for the global burden
of disease in 2001 indicate that hookworms cause even
greater disease burden than previously believed (WHO,
2002). Hookworm exceeds conditions such as schistosomiasis and both hepatitis B and C. New data on the epidemiology of iron deficiency anemia in East Africa indicate that hookworm accounts for a large percentage
of the huge DALY estimates resulting from this condition (Stoltzfus et al., 1997a; Stoltzfus et al., 1997b; Dreyfuss et al., 2000). Iron deficiency anemia currently accounts for a higher percentage of DALYs than HIV-AIDS
and is almost as important as malaria! Hookworm-associated iron deficiency has been noted to be particularly
common in coastal communities in the tropics (Lwambo
et al., 1991). The observation that hookworm anemia occurs in an estimated 44 million women in pregnancy with
resultant health consequences for the fetus and newborn
(Bundy et al., 1995), will likely add to these disease burden estimates.
Newer findings that hookworms may induce a state of
host immunological hyporesponsiveness (see below) and
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could promote susceptibility to intercurrent viral, bacterial or protozoan infections such as measles, HIV-AIDS
(Borkow et al., 2000; Wolday et al., 2002) and tuberculosis (Borkow and Bentwich, 2000; Borkow et al., 2001) have
tremendous importance in areas where these diseases
overlap. High rates of hookworm are known to occur in
Subsaharan Africa (Albonico et al., 1995; Behnke et al.,
2000; Bradley et al., 1993; Brooker et al., 2000a; Brooker et
al., 2000b; Lwambo et al., 1999; Palmer and Bundy, 1995;
Partnership for Child Development, 1998; Stoltzfus et
al., 2001; Stephenson et al., 1989), South China (Hotez et
al., 1997; Liu et al., 1999; Zhan et al., 2000; Gandhi et al.,
2001; Bethony et al., 2002; Hotez, 2002), Southeast Asia
(Humphries et al., 1997), India and Nepal (Haswell-Elkins et al., 1988; Dreyfuss et al., 2000), and in the Americas (Bloch and Rivera, 1977; Labiano-Abello et al., 1999).
In each of these regions HIV-AIDS is spreading rapidly.
Therefore, a firm link between hookworm and HIV-AIDS
would forever alter our concept of the importance of
hookworm as a cause of global disease burden.
2. The emerging epidemiology of hookworm
Traditionally, the epidemiology of hookworm has
been considered to be much like other soil-transmitted
helminth infections, such as ascariasis and trichuriasis,
i.e., an infection in which the heaviest worm burdens occur in children of school age (Bundy, 1990). Indeed, the
clinical effects of pediatric hookworm anemia are well described in the literature (Hotez, 1989), including physical,
mental and cognitive growth retardation effects (Smilie
and Augustine, 1926; Hotez, 1989; Sakti et al., 1999; Beasley et al., 2002; Lwambo et al., 2000; Hotez, 2000; Stoltzfus
et al., 2001).
While heavy hookworm burdens still occur among
children in some tropical areas (Stephenson et al., 1989;
Labiano-Abello et al., 1999), studies conducted worldwide
within the last decade indicate that the peak prevalence
and infection intensities for hookworm often occur in individuals in middle age, or even the elderly (Gandhi et
al., 2001; Bethony et al., 2002). Shown in Figure 1 are the
relationships between age and prevalence or age and intensity of hookworm in two different helminth-endemic
regions of China (Hainan Province) and Brazil (Minas
Gerias State). These represent areas of high hookworm
transmission and endemicity (Gandhi et al., 2001; Bethony
et al., 2002), and demonstrate that both prevalence and intensity increase as a function of age. Especially striking
is the strong correlation (r = 0.69; P < 0.001) between age
and egg counts shown in Hainan. In the Hainan study, a
variance components analysis revealed that age and gender made the most important contributions to infection
intensity (28–30%), with age alone responsible for 27%
of this variation (Bethony et al., 2002). Figure 2 compares
the age-related intensities of hookworm infections in both
Hainan and Minas Gerias with other endemic helminth
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Figure 1. The prevalence and intensity of infection with Necator americanus increases with age in two endemic areas: Hainan Province, People’s Republic of China (1999) and Minas Gerias, Brazil (2000). Data are from cross-sectional studies. Analysis of variance showed that egg counts were
significantly different (P < 0.001) among the age intervals, and that the eldest four age intervals were significantly different (P < 0.05) from the
younger age intervals, but not different from each other.

infections. In Hainan, Ascaris and Trichuris infections decrease after the age of 20, while in Minas Gerias the intensity of schistosomiasis diminishes after the age of 10. This
is in distinct contrast to hookworm epidemiologic patterns. Similar patterns for infection have been observed in
other N. americanus endemic areas (Liu et al., 1999; Wang
et al., 1999; Zhan et al., 2000; Humphries et al., 1997).
The association between increasing age and increasing
prevalence and hookworm burden reveals an important
public health problem for developing countries, since the
elderly are seldom mentioned as a group either at high-

risk for infection or the consequent morbidity associated
with high worm burdens. The influence of aging on the
prevalence and intensity of Necator infection has important public health consequences. In some parts of the developing world, such as China, the elderly are one of the
most rapidly expanding age groups (Hotez, 2002).
The mechanisms by which hookworms establish
chronic infections among the middle-aged and elderly are
under active investigation. Increasing evidence suggests
that this phenomenon may have an immunologic basis. In
Papua New Guinea, Quinnell et al. (1993, 1995) observed

Figure 2. The age distribution of Necator americanus differs from other soil-transmitted helminths such as Ascaris lumbricoides, Trichuris trichiura,
as well as Schistosoma mansoni. Panel A shows the relationship between age and infection intensity for three STHs in a cross-sectional study from
Hainan, People’s Republic of China. Ascaris lumbricoides and Trichuris trichiura epgs peak among children and then decline into adulthood. The
intensity of infection with Necator americanus increases with age, peaking in eldest age category (80+). Panel B shows the distribution for Necator americanus in relation to other helminth infections, from Minas Gerais, Brazil. The distribution of Schistosoma mansoni infection intensity shows
a traditional convex curve with age, increasing dramatically in young adults. The intensity of infection with Necator americanus again increases
steadily with age, peaking in the eldest age categories.
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that experience with hookworm infection does not confer
resistance, except in a selected few individuals who somehow acquire specific IgE responses against hookworm antigens (Pritchard and Walsh, 1995; Pritchard et al., 1995).
Susceptibility to reinfection was confirmed among volunteers who remained susceptible to hookworm reinfection
even after infecting themselves with N. americanus (Maxwell et al., 1987). In support of the inability of the human
host to mount natural immunity to Necator infection is the
preliminary observation that hookworm antigens may interfere with host lymphoproliferation and IL-4 levels during chronic infections (J. M. Bethony and M. E. Bottazzi,
unpublished observations). This might even be an active
immunosuppressive process that occurs through hookworm-derived secreted antigens. Several investigators
have isolated and characterized hookworm macromolecules that interfere with host cellular immune responses
(Moyle et al., 1994; Culley et al., 2000).

3. Rationale for hookworm vaccine development
The steady increase of hookworm burdens as a function
of age and the apparent absence of naturally acquired immunity in endemic areas have serious implications for national and international control efforts. The public health
control of hookworm and other soil-transmitted helminths
currently relies heavily on the use of benzimidazole anthelminthic drugs, especially albendazole (Albonico et
al., 1999). However, studies sponsored by the WHO and
other organizations have shown that high rates of hookworm reinfection can occur within just a few months following benzimidazole treatments (Albonico et al., 1995).
Presumably because of the absence of acquired immunity
following natural infection, treated individuals remain susceptible to reinfection following exposure to third-stage infective hookworm larvae (L3) in the soil. This biological
feature of the host–parasite relationship greatly limits the
sustainability of anthelminthic chemotherapy-based control. In addition, most anthelminthic deworming programs
worldwide currently target children in order to improve
their physical growth, school performance, and cognitive
development. While this approach might effectively, over
time, reduce endemic exposure and worm burdens for Ascaris and Trichuris infections, there is no reason to believe
that it would have an impact on endemic hookworm. It is
therefore not surprising to discover that more than 1.2 billion individuals are infected with hookworms despite the
widespread availability of albendazole.
An additional concern regarding the feasibility of sustainable control with benzimidazoles is the possibility of
emerging anthelminthic drug resistance among human
hookworm populations. In some nematode species benzimidazole resistance occurs secondary to the spread of a
single point mutation in nematode tubulin alleles. This
phenomenon has already resulted in widespread benzimidazole resistance among soil-transmitted helminths of
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ruminant livestock in the Southern Hemisphere (Conder
and Campbell, 1995), and might partially account for an
observed failure of mebendazole chemotherapy for human hookworm in southern Mali (De Clercq et al., 1997).
The unique epidemiology of hookworms resulting
from their apparent immunosuppressive properties, together with the potential for emerging anthelminthic resistance, necessitates a search for alternative or complementary approaches to public health control that do not
rely exclusively on anthelminthics. One approach for consideration is the development and use of anti-hookworm
vaccines.
4. Feasibility of hookworm vaccine development
Is it feasible to develop a vaccine for an infection in
which natural experience with the pathogen does not confer immunity? The concept of natural acquisition of immunity was, after all, the cornerstone for the development of
first-generation attenuated vaccines against poliomyelitis, measles, and numerous other infections. A central challenge for hookworm vaccine development will be to stimulate an artificial immune response that is unique and
results in disease burden reduction. In this sense, an antihookworm vaccine must overcome hurdles similar to those
faced by vaccinologists who tackle HIV-AIDS and malaria.
Existing evidence that it is feasible to vaccinate against
hookworms is based on three independent lines of research (Hotez et al., 1996, 1999, in press):
1. Studies first conducted in the Department of Helminthology at the Johns Hopkins School of Hygiene and
Public Health during the 1930s in dogs and mice demonstrated that artificial immunity against challenge
infections with Ancylostoma caninum L3 could be obtained by administering multiple inocula of living L3
either orally or subcutaneously (McCoy, 1931, Foster,
1935; Kerr, 1936; Otto and Kerr, 1939). The immunity
conferred using multiple doses of living L3 was shown
to be antibody mediated and could be administered
passively (Otto, 1940, 1941). Typically, the immunity
elicited by living L3 “vaccination” was not sterilizing
but instead operated by reducing hookworm burdens
relative to non-vaccinated control animals. The L3-vaccinated dogs were protected against hookworm disease characterized by heavy intestinal blood loss, but
they were not protected against hookworm infection.
Following very heavy challenge infections the mortality of severe hookworm disease was prevented by vaccination. Subsequent studies on the mechanisms of
vaccine immunity demonstrated that host immune responses were directed primarily against the antigens
secreted by L3 during host entry (Sarles, 1938; Taliaferro and Sarles, 1939; Sheldon and Groover, 1942).
2. Later, during the 1960s, the principles established by
the development of living L3 vaccines were employed
to develop an attenuated hookworm vaccine. This was
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accomplished by first damaging A. caninum L3 with
ionizing radiation, including X-rays, gamma-rays and
ultraviolet light (Miller, 1971, 1978, 1987). The irradiated L3 needed to remain viable in order for the vaccine to work—presumably viability was essential in
order to ensure that the damaged L3 continued to secrete antigens after host entry. Ionizing radiation allowed the vaccinator to increase the dose of L3 used in
an inoculum thereby decreasing the number of doses
required to achieve effective immunity. Ultimately, an
attenuated canine hookworm vaccine was developed
and marketed first in Florida and later in the Eastern
United States during the early 1970s (Miller, 1978).
The product soon failed commercially, however, because of its high production costs, limited shelf-life viability and inability on the part of both pet owner and
veterinarian to appreciate how a vaccine that does
not elicit sterilizing immunity (i.e., does not prevent
against hookworm infection) is still useful for protecting against hookworm disease.
3. Extracts of the esophagus of adult A. caninum elicit acquired immunity (Thorson, 1956). This parasite organ is enriched with proteases and much of the antibody in vaccinated dogs has the capacity to neutralize
parasite protease activity (Thorson, 1956). These efforts confirmed a prediction first made by Asa Chandler during the 1930s that anti-enzyme antibodies have
importance in mediating protective immunity against
helminths (Chandler, 1932, 1936). More recently, studies conducted to develop a vaccine against Haemonchus
contortus, a blood-feeding trichostrongyle nematode of
sheep that is phylogenetically related to hookworms,
identified the major antigens aligning the brush border membrane of the blood-feeding adult parasite alimentary canal (Knox, 2000). Among these antigens
are parasite gut-derived glycoproteins that comprise
a complex of proteases and other components (designated “H-gal-GP”), which bind to peanut lectin. Although the H-gal-GP complex is not ordinarily recognized during natural infection, and is considered a
hidden antigen, the complex when administered with
a saponin-derived adjuvant (Quil A) elicits high levels
of vaccine protection with respect to adult worm burdens and fecundity (Knox and Smith, 2001).
To summarize, the feasibility of developing anti-hookworm vaccines is based on more than 70 years of successful protection in laboratory animals, which is elicited either by living L3 and their secreted antigens or by the
antigens comprising the adult parasite alimentary canal.

5. Hookworm antigen discovery and selection
Hookworm antigens were selected as lead candidates
for further testing on the basis of their link with either attenuated larval vaccines or the H-gal-GP complex.
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5.1. L3 secreted antigens
Progress on attenuated hookworm larval vaccines
pointed to the importance of secreted L3 antigens as the
major immunogenic macromolecules associated with
vaccine protection. However, it was found that A. caninum L3 constitutively release only trace amounts of protein (Hawdon et al., 1995). A major breakthrough was
the observation that L3, stimulated at 37 °C in the presence of a cocktail composed of an ultrafiltrate of canine
serum and glutathione (or its derivatives), release comparatively large amounts of parasite-derived proteins
(Hawdon and Hotez, 1996; Hawdon et al., 1995, 1996,
1999; Zhan et al., 2002a). This observation made it possible to isolate the major secreted L3 antigens, obtain partial amino acid sequences of the purified proteins, and
subsequently clone and sequence their corresponding
cDNAs.
5.1.1. Ancylostoma secreted proteins
The two most abundant gene products released by L3
under host-stimulatory conditions are cysteine-rich secretory proteins (CRISPs) belonging to the pathogenesis
related protein (PRP) superfamily. The PRP superfamily
is composed of a phylogenetically diverse array of animal and plant proteins including insect venom allergens,
mammalian testis and epidydimal proteins, and plantpathogenesis related protein (Henriksen et al., 2001). The
major L3 Ancylostoma secreted proteins (ASPs) are composed of ASP-2 (Hawdon et al., 1999), a 24 kDa protein
with a single PRP domain, and ASP-1 a 45 kDa double
PRP domain protein corresponding to a heterodimorphic
repeat (Hawdon et al., 1996). Isolation of approximately
100 pmoles of each protein required the collection of up
to 300,000 A. caninum L3, which were obtained by coproculture from the feces of infected donor dogs. This was
followed by partial amino acid sequencing of the purified protein and then the synthesis of degenerate oligonucleotides for cDNA library screening (Hawdon et al.,
1996, 1999). Orthologues of both asp-1 and asp-2 cDNAs
were also subsequently isolated and cloned from A. duodenale, Ancylostoma ceylancium and N. americanus (Zhan et
al., 1999). The orthologues exhibit high degrees of amino
acid sequence similarity to each other. For instance, the N.
americanus ASP-1 (Na-ASP-1) exhibits 97% identity to A.
caninum ASP-1 (Ac-ASP-1).
The biological function of the ASPs is not known.
One study conducted with an ASP orthologue from Onchocerca volvulus suggests that it may exhibit angiogenic
properties (Tawe et al., 2000). However, ASP orthologues
are also present in the free-living nematode Caenorhabditis
elegans and the plant pathogen Meloidogyne incognita, and
therefore also presumably have a function that is unrelated to the host–parasite relationship. Adult hookworms
also produce single and double domain ASPs, which immunolocalize to a number of different nematode organs
including the cuticle, cephalic glands, and the brush border of the alimentary canal (Zhan et al., 2003).
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There are several lines of evidence that point to the
ASPs as promising vaccine candidates: (1) Natural product single and double domain ASPs were shown to protect sheep and guinea pigs against challenge infections
with H. contortus (Kooyman et al., 2000; Sharp et al., 1992;
Sharp and Wagland, 1998; Schallig et al., 1997a, 1997b,
1997c). Vaccine protection relies on the presence of high
levels of anti-ASP IgE (Kooyman et al., 2000). (2) Antibodies obtained from the abomasal mucus and draining
lymph nodes from calves immunized with multiple infections of Ostertagia ostertagi recognize an ASP orthologue
(De Maere et al., 2002). In addition fractions of helminth
antigens that protect cattle against O. ostertagi infection
are enriched in single domain ASPs (Geldhof et al., 2003).
(3) Vaccination of mice with a recombinant Escherichia coli
fusion protein composed of a polyhistidine tag and amino
acids 96–424 of either Ac-ASP-1 or Na-ASP-1 results in
host immune responses, which inhibit the extra-intestinal migration of A. caninum L3 into the lungs following oral infection (Ghosh et al., 1996; Ghosh and Hotez,
1999; Liu et al., 2000). Anti-Ac-ASP-1 antibody also passively protects against larval migration (Ghosh and Hotez, 1999). (4) In two cross-sectional epidemiologic studies it was determined that residents of Hainan Province,
China and Minas Gerais State, Brazil who harbor less intense hookworm burdens (as measured by quantitative
egg counts) exhibit high titers of circulating antibodies
against a single domain ASP from L3 (Jeff Bethony, unpublished observation).
5.1.2. Astacin-like metalloprotease (MTP)
Hookworm L3 also releases a 62 kDa zinc metalloprotease upon host-stimulation (Zhan et al., 2002a). The MTP1 enzyme is of the astacin class represented by a metalloprotease from the crayfish Astacus astacus. In addition to
a catalytic domain composed of zinc in the enzyme active
site coordinated by the imidazoles of conserved histidine
residues, MTP-1 also contains an epidermal growth factor
domain of unknown function. MTP-1 is an immunodominant protein and was first cloned and isolated by screening an A. caninum cDNA expression library with pooled
sera from hookworm-infected individuals who harbor
low worm burdens and are putatively resistant (Zhan et
al., 2002a). Calves immunized with O. ostertagi L3 also recognize an MTP-1 orthologue (De Maere et al., 2002). Studies examining the vaccine potential of Ac-MTP-1 from A.
caninum are under evaluation, as is an orthologue from
Ancylostoma ceylanicum (see below).
5.1.3. Other L3 antigens
In addition to the ASPs and MTP-1, Ancylostoma L3
also releases macromolecules with amino acid similarities to a 60 kDa acetylcholinesterase (ACH) and a 16 kDa
(144 amino acids) putative transthyreitin (TTR), which
may bind retinol binding proteins (Hawdon et al., un-
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published). Previously, a secreted acetylcholinesterase
has shown promise as a vaccine target against Dictyocaulus viviparous (McKeand, 2000) and Trichostrongylus colubriformis (Griffiths and Pritchard, 1994). Each of these
proteins is being evaluated as vaccine candidates, as is a
hookworm L3 surface protein similar to Ov-103 from O.
volvulus.
5.2. Adult hookworm antigens
5.2.1. Secreted antigens
There is no evidence that the excretory–secretory proteins released by adult hookworms elicit high levels of
vaccine protection. The major protein secreted by adult
hookworms is TMP, a 16 kDa orthologue of mammalian
tissue inhibitor of metalloprotease (Zhan et al., 2002b). AcTMP comprises almost 10% of the protein secreted in vitro by adult A. caninum (Zhan et al., 2002b). The function
of this molecule for adult hookworms at the site of attachment in the mammalian intestine is unknown. However,
of interest is the observation that regions of amino acid
sequence similarity between Ac-TMP and mammalian
TIMPs are not those predicted to be in contact with their
target matrix metalloproteases (Zhan et al., 2002b). This
suggests the possibility that Ac-TMP has a function other
than metalloprotease inhibition. In addition to TMP, adult
A. caninum hookworms also release serine protease inhibitors including those involved in the coagulation cascade
such as factor Xa (Cappello et al., 1995, 1996) and VIIa-tissue factor (Stanssens et al., 1996), and some adult-specific
ASPs (Zhan et al., in press).
5.2.2. H-gal-GP orthologues
The H-gal-GP complex from the brush border of the
alimentary canal of H. contortus is composed of multiple
components including a metalloendopeptidase of the neprilysin family, an aspartic protease, a cysteinyl protease,
a cystatin, a thrombospondin orthologue, and a galectin
(Knox, 2000). As noted above, the complex elicits high levels of protection against H. contortus challenge infections
in sheep (Knox, 2000; Knox and Smith, 2001), although
each component has so far not been examined individually as a natural product. Orthologues of each of the protease components of the complex have been cloned from
hookworms including A. caninum-metalloendopeptidase1 (Ac-MEP-1) (Jones and Hotez, 2001), A. caninum-cysteinyl proteases (Ac-CP-1 and Ac-CP-2) (Harrop et al., 1995;
Loukas et al., 2000), and A. caninum-aspartic proteases
(Ac-APR-1 and Ac-APR-2) (Harrop et al., 1996; Williamson et al., 2002, 2003a, 2003b). Immunolocalization studies confirm that some of these proteases align the brush
border membrane of the alimentary canal of adult hookworms ( Figure 3). These proteases are believed to operate in a coordinated fashion to facilitate host hemoglobin degradation during blood feeding (Brinkworth et al.,
2000, 2001).
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gens are baculovirus, insect cells, and yeast. To date,
it has not been possible to predict which vector system
will work best. However, baculovirus and insect cells
will likely prove to be too expensive for the manufacture of a public sector hookworm vaccine. Leading the
yeast expression vectors is the methanol-utilizing organism Pichia pastoris, which produces proteins in high
yields and is relatively inexpensive compared to other
eukaryotic expression systems.

Figure 3. Immunolocalization of Ac-MEP-1 (neprilysin-like adult
hookworm metalloprotease) to the brush border membrane of the
adult hookworm alimentary canal.

6. The rules of engagement
Work conducted during the decade of the 1990s on H. contortus vaccine protection experiments in sheep and A. caninum vaccine protection experiments in mice has provided
some useful paradigms that might be applicable to preclinical vaccine protection experiments in laboratory animals.
1. Many of the candidate vaccine antigens under evaluation are hydrolytic enzymes, including proteases and
acetylcholinesterases from L3 and adult stages. While
the natural products isolated from parasites typically maintain their enzymatic activity, the activity is
lost when the protease cDNAs are expressed in E. coli.
Therefore, expression of bioactive molecules usually
requires eukaryotic vectors.
2. Similarly, in instances where natural product antigens
protect against challenge infections, the corresponding recombinant protein expressed in E. coli fails to reproduce the protection. In most cases this is because the
conformational epitopes are lost during E. coli expression. Incorrect disulphide bond formation probably accounts for most of the lost epitope expression, particularly for cysteine-rich proteins like the ASPs, rather than
the absence of correct glycosylation. The failure of E. coli
to produce correctly folded antigens for vaccination was
observed for L3 ASPs from H. contortus (Sharp and Wagland, 1998) and A. caninum (see below), and for the Hgal-GP complex components (Knox and Smith, 2001).
3. In some cases eukaryotic expression restores the conformational epitopes lost during E. coli expression.
This has been demonstrated for baculovirus expressed
ASP from H. contortus (Sharp and Wagland, 1998) and
yeast-expressed Ac-ASP-1 (see below).
4. Among the eukaryotic vectors that have been employed to express candidate nematode vaccine anti-

5. In the few studies that have attempted to define the
mechanisms associated with vaccine protection, achieving high levels of host antibody is required for reduction in worm burdens (Ghosh and Hotez, 1999). In some
cases host IgE may be the principal effector antibody.
This was suggested by the finding that low H. contortus worm burdens in sheep associated with high levels
of IgE directed H. contortus ASP (Kooyman et al., 2000).
The importance of IgE antibody is also underscored by
preliminary epidemiologic data suggesting that host
IgE directed against ASP-2 was associated with reduced
hookworm intensity, as determined by quantitative egg
counts (Jeff Bethony, unpublished data).
6. Achieving high levels of host antibody using baculovirus, insect cell, or yeast-expressed proteins will be
challenging, particularly when these proteins are formulated with aluminum-based adjuvants such as alum
or alhydrogel. The requirement for high levels of immunogenicity has prompted the search for alternative
adjuvants.
7. Hookworm antigen expression
Over the last 2 years, focused efforts have been made
to express the lead candidate antigens in both prokaryotic
and eukaryotic systems (Table 1).
7.1. L3 hookworm antigens
Expression of Na-asp-1, Ac-asp-2, and Ac-mtp-1 cDNAs
in E. coli has so far produced recombinant fusion proteins
containing polyhistidine tags, which are neither soluble
nor correctly refold in the absence of harsh denaturants,
including ionic detergents. In addition, the E. coli recombinant fusion proteins frequently are expressed in inclusion bodies that are heavily contaminated with other bacterial constituents. Frequently it is not possible to separate
the recombinant fusion proteins away from these contaminants. In the case of the ASPs, the high number cysteines (10 in ASP-2 and 20 ASP-1) presumably cause recombinant polypeptides to form with aberrant disulphide
bond formation. Recombinant E. coli Na-ASP-1 does not
exhibit conformational epitopes corresponding to the native protein. As shown in Figure 4, polyclonal antibodies
prepared against E. coli Na-ASP-1 fail to immunoprecipitate the corresponding native protein from soluble L3 extracts. Similarly, recombinant Ac-MTP-1 expressed in E.
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Description

MW (kDa)

Expression vector

Pathogenesis-related protein
Pathogenesis-related protein
Astacin metalloprotease
Transthyreitin
Acetylcholinesterase

45
24
62
16
60

Pichia pastoris
P. pastoris and insect cell
Baculovirus
Escherichia coli and P. pastoris
P. pastoris

99
45
35
35
24

Insect cells
Baculovirus
Insect cells and P. pastoris
P. pastoris
P. pastoris (pending)
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Table 1. Lead candidate hookworm vaccine antigens
Antigen
L3 secreted antigens
ASP-1
ASP-2
MTP-1
TTR
ACH

Adult gut-membrane antigens (H-gal-orthologues)
MEP-1
APR-2
CP-1
CP-2
ASP-5

Neprilysin metalloprotease
Aspartic protease
Cysteinyl protease
Cysteinyl protease
Pathogenesis-related protein

coli does not exhibit enzymatic activity. In order to overcome these hurdles and express recombinant proteins either having catalytic activity or appropriate conformational epitopes, their corresponding cDNAs had to be
re-engineered in eukaryotic vectors, including baculovirus, insect cells, or yeast. Polyclonal antibodies prepared
against P. pastoris expressed Na-ASP-1 immunoprecipitate the native protein from soluble L3 extracts (Figure
4). To date, the following L3 recombinant proteins have
been successfully expressed in P. pastoris: Na-ASP-1, NaASP-2, and Ac-TTR, from N. americanus and A. caninum,
respectively, as well as Ay-ASP-1 and Ay-ASP-2, the orthologues from A. ceylanicum. One of the L3 acetylcholinesterases has also been expressed (M. Selkirk, personal
communication). To date it has not been possible to express soluble Ac-MTP-1 and Ac-ASP-2 in yeast. However,
Ac-ASP-2 as well as catalytically active Ac-MTP-1 was recently expressed in baculovirus.

with L3 of A. ceylanicum and dogs challenged with L3 of
A. caninum. An advantage of the hamster model is its relatively low cost compared to dogs. In addition, hamsters
infected with A. ceylanicum experience weight and blood
loss similar to human disease from heavy infections (Bungiro et al., 2001). However, A. ceylanicum does not ordinarily cause intestinal blood loss in humans and the hamster is not a natural host for the parasite. In addition, the
number of adult hookworms that establish in hamsters
is low—this requires the use of large numbers of hamsters in order to achieve adequate sample sizes for comparing experimental and control groups. In contrast, dogs
are the natural hosts of A. caninum, and this model closely
resembles A. duodenale hookworm infection. The ability to achieve high adult worm burdens in the laboratory

7.2. Adult hookworm antigens
Two of the small protease inhibitors released by adult
A. caninum hookworms, Ac-TMP and Ac-AP (factor Xa
inhibitor anticoagulant peptide) have been expressed as
soluble recombinant fusion proteins in E. coli. However,
none of the H-gal-GP orthologous proteases expressed in
E. coli are soluble or exhibit enzymatic activity. Ac-MEP1, Ac-CP-1, a cysteinyl protease, and the aspartic proteases, in contrast have been expressed as bioactive, soluble
enzymes in either viral or non-viral insect cell expression
systems (Loukas, Williamson, et al., unpublished). Ac-CP2 has been expressed in P. pastoris in biologically active
form. Work is in progress to express the adult-stage-specific ASPs in eukaryotic systems (Zhan et al., in press).
8. Hookworm antigen-adjuvant formulation and
vaccine testing
Two laboratory animal systems are now in routine use
for preclinical vaccine development: hamsters challenged

Figure 4. Immunoprecipitation of Ac-ASP-1 from biotinylated extracts
of A. caninum L3. B, protein bound to strepavidin resin (immunoprecipitated). U, protein unbound to strepavidin resin (non-immunoprecipitated). Group A, canine antiserum to two doses of irradiated
A. caninum L3. Group B, canine antiserum to alum (adjuvant control). Group C, canine antiserum to Na-ASP-1 expressed in Pichia pastoris and administered with alum in four doses separated by 3 weeks.
Group D, canine antiserum to Na-ASP-1 expressed in Pichia pastoris
and administered with alum in four doses on days 1, 4, 60, and 64.
Group E, canine antiserum to Na-ASP-1 expressed in Escherichia coli
and administered with alum in four doses on days 1, 4, 60, and 64.
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Figure 5. Comparison of antigen-specific IgG1, IgG2, and IgE canine antibody titers in purpose-bred beagle dogs (n = 5 per group) vaccinated with
150 μg of Escherichia coli Na-ASP-1 (four doses) or Pichia pastoris Na-ASP-1 (four doses using two different schedules). An additional group of dogs
(n = 5) was vaccinated with A. caninum irradiated L3 (two doses).

reduces the sample size required for comparing experimental and control groups. For vaccine studies, purposebred beagles are usually vaccinated with hookworm antigens formulated with adjuvants beginning at 8–10 weeks
of age. Up to 2 months are usually required to complete
the immunization series, followed by challenge infections
(Hotez et al., 2002).
In addition to the two Ancylostoma systems under investigation, some efforts have been made to adapt N.
americanus to laboratory hamsters. Recently, Xiao Shuhua
and his colleagues adapted N. americanus by passing it
through 100 generations in a Chinese strain of the golden
hamster (Xue et al., in press). By doing so, they have obviated the requirement for exogenous steroids and can obtain reasonable levels of adult hookworm burdens by infecting hamsters at 9–10 weeks of age. In contrast, other
investigators have had to rely on infecting neonatal hamsters (Behnke and Pritchard, 1987).
To date, studies in dogs and hamsters have revealed that
E. coli recombinant fusion proteins are more immunogenic
than recombinant proteins expressed in baculovirus, insect
cells, or yeast. Shown in Figure 5 is a direct comparison of
pre-challenge antibody titers in dogs (five per group) vaccinated either with E. coli Na-ASP-1 or P. pastoris Na-ASP-1
formulated with alhydrogel. The former exhibits far higher
IgG2 antibody titers, although the IgG1 and IgE responses
are similar. However, it is not clear whether the IgG2 responses might be directed against bacterial lipopolysaccharide or E. coli protein contaminants. As noted above
(Figure 4), many of the peptide sequences recognized by
canine anti-E. coli-Na-ASP-1 do not correspond to conformational epitopes on the native protein.
The comparatively low immunogenicity of eukaryotic recombinant hookworm antigens formulated with
aluminum-based adjuvants (e.g., alum and alhydrogel)
points out a new requirement to explore alternative adjuvants. Among those under investigation, are oil–water
emulsions such as montanide ISA-720 (Seppic) and ASO3
(GlaxoSmithKline), as well as adjuvants containing saponin derivatives such as ASO2 (GlaxoSmithKline) and
Quil A. ASO2 is an oil–water emulsion that contains QS-

21 (derived from saponin) and a lipid A derivative. Both
ISA-720 and ASO2 have been used successfully in human
clinical trials (Bojang et al., 2001; Doherty et al., 1999).
The importance of eliciting strong immune responses
against the candidate recombinant hookworm antigens
is highlighted by studies, which examine the relationship between antibody titers and hookworm burdens. As
shown in Figure 6, high levels of antigen-specific IgE directed against recombinant E. coli Na-ASP-1 and Ac-TTR
inversely correlate with hookworm burdens. In the case
of E. coli Ac-MTP-1, the inverse relationship between antibody titer and worm burden is best correlated with IgG2
(Figure 6). Because many of these antibodies directed
against these E. coli proteins probably do not recognize
conformational epitopes, the levels of vaccine protection should improve significantly by employing recombinant antigens expressed in eukaryotic systems. Also of
great promise is the exploitation of new platform technologies for the development of anti-hookworm vaccines, including the use of hepatitis B core particles for the expression of peptide epitopes from candidate vaccine antigens
(Birkett et al., 2002). Among them are amino acids 291–
303 of Na-ASP-1, which correspond to a predicted hydrophilic loop in the native molecule.
To summarize, each of the lead antigens has been expressed in eukaryotic vectors and is now under evaluation as candidate vaccines in one or more of three different laboratory animal challenge models (A. caninum in
dogs, A. ceylanicum in hamsters and N. americanus in hamsters). Results from these studies will provide the basis
for up-selection leading to process development and pilot manufacture.
9. Future prospects
Even after process development and pilot manufacture
is completed, however, there are still a number of hurdles
that must be overcome before an anti-hookworm vaccine
is produced for the developing world. Among them are
the following.
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1. No human clinical trials have ever been conducted with
a recombinant nematode vaccine.
2. Preliminary studies conducted in Brazil suggest that
patients chronically infected with hookworm are functionally immunosuppressed and do not develop lymphoproliferative responses to hookworm antigens
(J. Bethony and M. E. Bottazzi, unpublished observations). However, some patients who are treated for
hookworm with anthelminthic drugs acquire a renewed capacity to respond to hookworm antigens.
This suggests that human anti-hookworm vaccinations
may need to be preceded by an initial round of anthelminthic treatment.
3. Little is known on the role of cross reactivity and regulation of the immune response in individuals carrying more than a single helminthic infection, or its correlation with the development of resistance to infection
and reinfection.
4. If the requirement to develop IgE responses against
some of the lead candidate hookworm vaccine antigens is confirmed, then it may become necessary to
choose adjuvant formulations and doses designed to
enhance allergic-type responses. This could contribute
to the vaccine’s ultimate toxicity.
5. Many of the hookworm antigens selected for further
development contain partial amino acid sequences
that are homologous with mammalian proteins. The
potential for cross reactivity to autoantigens require
investigation.
6. Hookworm is a disease of the “poorest of the poor” in
the developing nations of the tropics. For this reason,
there is practically no commercial market for an antihookworm vaccine. The institutions for developing
and manufacturing public sector vaccines are still rudimentary. This is particularly unfortunate, given that
the next generation of vaccines for diseases in developing countries, e.g., hookworm, HIV-AIDS, malaria,
will require high levels of technological sophistication
(Hotez, 2001; Broder et al., 2002).
7. Immunity to hookworm vaccines must be long-lasting
in order to protect at-risk individuals exposed to hookworm L3 in adulthood.
8. The geographic variation of the candidate hookworm
antigen amino acid sequences is largely unknown.
However, preliminary studies with Na-ASP-1 indicate
that for this particular antigen, geographic variation is
not significant (J. Hawdon, unpublished observation).
Despite these obstacles, the potential impact of developing a hookworm vaccine is huge. Because of its contribution to the burden of disease caused by iron deficiency
anemia, hookworm is arguably the most significant human helminth pathogen worldwide. Its possible role in
promoting increased susceptibility to other intercurrent
pathogens, including HIV-AIDS will ensure hookworm’s
disease burden impact.

Figure 6. Inverse relationships of antibody titers to Escherichia coli expressed recombinant fusion proteins to hookworm burden in vaccinated dogs. Purpose-bred beagles were vaccinated at 8–10 weeks of
age and each received three to four doses of the recombinant protein
formulated with an aluminum-based adjuvant for ASO2 (GlaxoSmithKline). (A) Anti-Na-ASP-1 IgE, (B) anti-Ac-MTP-1 IgG2, (C) anti-TTR
IgE. Figure 6B was modified from a figure published in Hotez et al.
(2002).
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